Healthcare
The Joint Corp.(JYNT)
Live Price
Offline$9.34
+2.41% today
1Y Change
-18.61%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $130.00M
- Revenue Growth
- +5.2%
- EPS Growth
- +133.3%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
The Joint Corp. (JYNT) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $9.34 and down 18.6% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +5.2%, EPS growth of +133.3%, a dividend yield of 0.0%. What stands out right now is revenue +5.2%, EPS +133.3%, free cash flow -95.9% with operating margin -1.6% and ROIC -3.2%. Valuation already assumes a fairly strong business story at P/E 44.3 and price/sales 2.3. Stock Foundry combines JYNT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.2% vs +7.6% peer median
Operating Margin
Below sector median
-1.6% vs +19.4% peer median
P/E
Above sector median
44.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 7, 2026 with an EPS surprise of +166.7% and a revenue surprise of +2.2%.
The operating story is still moving forward
Revenue is running at +5.2% and EPS at +133.3%, with operating margin around -1.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | +166.7% | +0.2% | -5.3% | -4.4% |
2026 Mar 12, 2026 | +20.0% | +2.3% | -0.5% | +6.3% |
2025 Nov 6, 2025 | +300.0% | -3.9% | +3.5% | +6.1% |
Benchmark Edge
JYNT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
JYNT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
JYNT Max Drawdown
-36.03%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JYNT and SPY.
Company Overview
The Joint Corp.
NASDAQ Capital Market
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
- Leadership
- Sanjiv Razdan
- IPO Date
- Nov 11, 2014
- Employees
- 443
- Street Address
- 16767 North Perimeter Drive
- Mailing
- Scottsdale, AZ, 85260
- Region
- Scottsdale, AZ, US
- Reporting Currency
- USD
- Investor Line
- 480 245 5960
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 44.3
- EV/EBITDA
- 92.9
- Price/Sales
- 2.3
- Price/Book
- 8.6
Growth
- Revenue
- +5.2%
- EPS
- +133.3%
- Free Cash Flow
- -95.9%
Profitability
- Gross Margin
- 76.6%
- Operating Margin
- -1.6%
- Net Margin
- 5.3%
- ROE
- 14.4%
- ROIC
- -3.2%
Balance Sheet
- Debt/Equity
- 0.13
- Current Ratio
- 1.59
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.